Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: insulin degludec/liraglutideDrug: insulin glargine
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 420
- Registration Number
- NCT02773368
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT02773355
- Locations
- 🇲🇽
Novo Nordisk Investigational Site, Puebla, Mexico
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 543
- Registration Number
- NCT02762578
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Tianjin, China
A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: insulin degludec/liraglutide
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT02754817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: liraglutideDrug: alpha-glucosidase inhibitorsDrug: DPP-4 inhibitorsDrug: meglitinidesDrug: SGLT-2 inhibitorsDrug: sulphonylureaDrug: thiazolidinediones
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1991
- Registration Number
- NCT02730377
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placeboDrug: liraglutide
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT02717858
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Hellerup, Denmark
A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placeboDrug: liraglutide
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02696148
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Memphis, Tennessee, United States
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: placeboDrug: semaglutide
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3183
- Registration Number
- NCT02692716
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 834
- Registration Number
- NCT02670915
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine
A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
- Conditions
- Congenital Bleeding DisorderCongenital FXIII Deficiency
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8
- Registration Number
- NCT02670213
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath